SVB Securities initiated coverage of Selecta Biosciences (NASDAQ:SELB) with an “outperform” rating and $7 price target. The stock closed at 88 cents on June 3. Selecta is a clinical-stage biotech company advancing its...
William Blair upgraded Selecta Biosciences (NASDAQ:SELB) to “outperform,” citing multiple upcoming positive risk/reward catalysts for the company. The stock closed at $3.90 on March 11. The company’s ImmTOR platform...
Selecta Biosciences’ (NASDAQ:SELB) MMA-101 received FDA orphan drug designation for the treatment of methylmalonic acidemia (MMA). MMA is caused by a mutation in the methylmalonyl-CoA mutase gene, which results in the...
Selecta Biosciences’ (NASDAQ:SELB) MMA-101 received FDA rare pediatric disease designation for the treatment of methylmalonic acidemia (MMA). MMA is caused by a mutation in the methylmalonyl-CoA mutase gene, which...
William Blair downgraded Selecta Biosciences (NASDAQ:SELB) to “market perform” after the company and partner, Swedish Orphan Biovitrum, announced top-line data from the Phase 2 COMPARE trial, comparing Selecta’s SEL-212...
Stifel downgraded Selecta Biosciences (NASDAQ:SELB) to “hold” from “buy” with a price target of $4 after the company inked a licensing deal for its SEL-212 drug candidate for the treatment of severe chronic gout with...
William Blair initiated coverage of Selecta Biosciences (NASDAQ:SELB) with an “outperform” rating and fair value estimated of $9. The stock closed at $3.14 on Jan. 17. Selecta is focused on its ImmTOR platform, which...
Selecta Biosciences (NASDAQ:SELB) completed enrollment in its Phase 2 COMPARE trial of SEL-212 for the treatment of chronic refractory gout. SEL-212 is designed to sustain control of serum uric acid (SUA) levels in...